File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Famotidine Is Inferior to Pantoprazole in Preventing Recurrence of Aspirin-Related Peptic Ulcers or Erosions

TitleFamotidine Is Inferior to Pantoprazole in Preventing Recurrence of Aspirin-Related Peptic Ulcers or Erosions
Authors
Issue Date2010
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastro
Citation
Gastroenterology, 2010, v. 138 n. 1, p. 82-88 How to Cite?
AbstractBackground & Aims: Little is known about the efficacy of H 2-receptor antagonists in preventing recurrence of aspirin-related peptic ulcers. We compared the efficacy of high-dose famotidine with that of pantoprazole in preventing recurrent symptomatic ulcers/erosions. Methods: We performed a randomized, double-blind, controlled trial of 160 patients with aspirin-related peptic ulcers/erosions, with or without a history of bleeding. Patients were given either famotidine (40 mg, morning and evening) or pantoprazole (20 mg in the morning and placebo in the evening). All patients continued to receive aspirin (80 mg daily). The primary end point was recurrent dyspeptic or bleeding ulcers/erosions within 48 weeks. Results: A total of 130 patients (81.1%) completed the study; 13 of 65 patients in the famotidine group reached the primary end point (20.0%; 95% one-sided confidence interval [CI] for the risk difference, 0.1184-1.0) compared with 0 of 65 patients in the pantoprazole group (P < .0001, 95% one-sided CI for the risk difference, 0.1184-1.0). Gastrointestinal bleeding was significantly more common in the famotidine group than the pantoprazole group (7.7% [5/65] vs 0% [0/65]; 95% one-sided CI for the risk difference, 0.0226-1.0; P = .0289), as was recurrent dyspepsia caused by ulcers/erosions (12.3% [8/65] vs 0% [0/65]; 95% one-sided CI for the risk difference, 0.0560-1.0; P = .0031). No patients had ulcer perforation or obstruction. Conclusions: In patients with aspirin-related peptic ulcers/erosions, high-dose famotidine therapy is inferior to pantoprazole in preventing recurrent dyspeptic or bleeding ulcers/erosions. © 2010 AGA Institute.
Persistent Identifierhttp://hdl.handle.net/10722/163286
ISSN
2014 Impact Factor: 16.716
2014 SCImago Journal Rankings: 5.616
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorNg, Fen_HK
dc.contributor.authorWong, Sen_HK
dc.contributor.authorLam, Ken_HK
dc.contributor.authorChu, Wen_HK
dc.contributor.authorChan, Pen_HK
dc.contributor.authorLing, Yen_HK
dc.contributor.authorKng, Cen_HK
dc.contributor.authorYuen, Wen_HK
dc.contributor.authorLau, Yen_HK
dc.contributor.authorKwan, Aen_HK
dc.contributor.authorWong, BCYen_HK
dc.date.accessioned2012-09-05T05:29:38Z-
dc.date.available2012-09-05T05:29:38Z-
dc.date.issued2010en_HK
dc.identifier.citationGastroenterology, 2010, v. 138 n. 1, p. 82-88en_HK
dc.identifier.issn0016-5085en_HK
dc.identifier.urihttp://hdl.handle.net/10722/163286-
dc.description.abstractBackground & Aims: Little is known about the efficacy of H 2-receptor antagonists in preventing recurrence of aspirin-related peptic ulcers. We compared the efficacy of high-dose famotidine with that of pantoprazole in preventing recurrent symptomatic ulcers/erosions. Methods: We performed a randomized, double-blind, controlled trial of 160 patients with aspirin-related peptic ulcers/erosions, with or without a history of bleeding. Patients were given either famotidine (40 mg, morning and evening) or pantoprazole (20 mg in the morning and placebo in the evening). All patients continued to receive aspirin (80 mg daily). The primary end point was recurrent dyspeptic or bleeding ulcers/erosions within 48 weeks. Results: A total of 130 patients (81.1%) completed the study; 13 of 65 patients in the famotidine group reached the primary end point (20.0%; 95% one-sided confidence interval [CI] for the risk difference, 0.1184-1.0) compared with 0 of 65 patients in the pantoprazole group (P < .0001, 95% one-sided CI for the risk difference, 0.1184-1.0). Gastrointestinal bleeding was significantly more common in the famotidine group than the pantoprazole group (7.7% [5/65] vs 0% [0/65]; 95% one-sided CI for the risk difference, 0.0226-1.0; P = .0289), as was recurrent dyspepsia caused by ulcers/erosions (12.3% [8/65] vs 0% [0/65]; 95% one-sided CI for the risk difference, 0.0560-1.0; P = .0031). No patients had ulcer perforation or obstruction. Conclusions: In patients with aspirin-related peptic ulcers/erosions, high-dose famotidine therapy is inferior to pantoprazole in preventing recurrent dyspeptic or bleeding ulcers/erosions. © 2010 AGA Institute.en_HK
dc.languageengen_US
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastroen_HK
dc.relation.ispartofGastroenterologyen_HK
dc.subject.mesh2-Pyridinylmethylsulfinylbenzimidazoles - Administration & Dosageen_US
dc.subject.meshAgeden_US
dc.subject.meshAnti-Bacterial Agents - Therapeutic Useen_US
dc.subject.meshAnti-Inflammatory Agents, Non-Steroidal - Adverse Effectsen_US
dc.subject.meshAnti-Ulcer Agents - Administration & Dosageen_US
dc.subject.meshAspirin - Adverse Effectsen_US
dc.subject.meshFamotidine - Administration & Dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshGastrointestinal Hemorrhage - Chemically Induced - Epidemiology - Prevention & Controlen_US
dc.subject.meshHelicobacter Infections - Drug Therapy - Epidemiologyen_US
dc.subject.meshHistamine H2 Antagonists - Administration & Dosageen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPeptic Ulcer - Chemically Induced - Epidemiology - Prevention & Controlen_US
dc.subject.meshRecurrence - Prevention & Controlen_US
dc.subject.meshRisk Factorsen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleFamotidine Is Inferior to Pantoprazole in Preventing Recurrence of Aspirin-Related Peptic Ulcers or Erosionsen_HK
dc.typeArticleen_HK
dc.identifier.emailLam, K: hrntlkf@hkucc.hku.hken_HK
dc.identifier.emailWong, BCY: bcywong@hku.hken_HK
dc.identifier.authorityLam, K=rp00718en_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1053/j.gastro.2009.09.063en_HK
dc.identifier.pmid19837071-
dc.identifier.scopuseid_2-s2.0-72249102783en_HK
dc.identifier.hkuros170560-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-72249102783&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume138en_HK
dc.identifier.issue1en_HK
dc.identifier.spage82en_HK
dc.identifier.epage88en_HK
dc.identifier.isiWOS:000273427700018-
dc.publisher.placeUnited Statesen_HK
dc.identifier.f10001797972-
dc.identifier.scopusauthoridNg, F=16936078000en_HK
dc.identifier.scopusauthoridWong, S=7404590845en_HK
dc.identifier.scopusauthoridLam, K=8948421200en_HK
dc.identifier.scopusauthoridChu, W=23995209500en_HK
dc.identifier.scopusauthoridChan, P=7403497841en_HK
dc.identifier.scopusauthoridLing, Y=35765387300en_HK
dc.identifier.scopusauthoridKng, C=7801364659en_HK
dc.identifier.scopusauthoridYuen, W=8608747200en_HK
dc.identifier.scopusauthoridLau, Y=35765428400en_HK
dc.identifier.scopusauthoridKwan, A=55223335800en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats